Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) EBT Margin: 2010-2025

Historic EBT Margin for Niagen Bioscience (NAGE) over the last 14 years, with Sep 2025 value amounting to 14.12%.

  • Niagen Bioscience's EBT Margin rose 678.00% to 14.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.04%, marking a year-over-year increase of 1542.00%. This contributed to the annual value of 8.89% for FY2024, which is 1480.00% up from last year.
  • Per Niagen Bioscience's latest filing, its EBT Margin stood at 14.12% for Q3 2025, which was up 17.60% from 12.01% recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's EBT Margin peaked at 25.70% during Q4 2024, and registered a low of -51.17% during Q3 2021.
  • Moreover, its 3-year median value for EBT Margin was 0.54% (2023), whereas its average is 4.53%.
  • As far as peak fluctuations go, Niagen Bioscience's EBT Margin slumped by 2,144bps in 2021, and later soared by 3,612bps in 2023.
  • Quarterly analysis of 5 years shows Niagen Bioscience's EBT Margin stood at -29.98% in 2021, then spiked by 2,311bps to -6.88% in 2022, then surged by 742bps to 0.54% in 2023, then spiked by 2,516bps to 25.70% in 2024, then spiked by 678bps to 14.12% in 2025.
  • Its last three reported values are 14.12% in Q3 2025, 12.01% for Q2 2025, and 17.16% during Q1 2025.